Men's Health is a urological subspecialty that is at the forefront of innovation, but little data exist evaluating the attitudes that andrologists have toward the current treatment modalities available for managing Men's Health conditions. A survey of 37 questions asking what providers would choose as treatment for common conditions was distributed online via Survey Monkey to members of the Sexual Medicine Society of North America and European Society for Sexual Medicine. A total of 115 respondents completed the survey after an initial screening question. For
erectile dysfunction (ED), 40%, 38%, and 33% of providers indicated that they would use
tadalafil daily,
tadalafil on demand, or
sildenafil on demand, respectively, as first-line
phosphodiesterase 5 inhibitor therapy. Furthermore, a total of 74% would elect to undergo low-intensity shockwave
therapy [67%], platelet rich plasma
injections [15%], and stem cell
injections [15%]. Sex/behavioral
therapy was preferred for both premature (36%) and delayed (52%) ejaculation. Approximately 44% of respondents indicated that they would undergo
Collagenase Clostridium Histolyticum injections for
Peyronie's Disease in the acute phase. In the setting of hypogonadal symptoms with borderline low total
testosterone levels (300-400 ng/dL), 69% of respondents would pursue
testosterone therapy. The prostatic lift procedure was the preferred procedure for men seeking symptom resolution with preservation of ejaculatory function. Many Men's Health specialists would pursue the least invasive options before considering procedural intervention for any given condition. Providers may shift their treatment preferences toward newer treatment modalities as longer term data become available.